EVERSANA's Alan Crowther on why MFN's three programs, compounding interactions with IRA and 340B, and leverage gaps make it pharma's most consequential pricing challenge.
Alan Crowther
Advertisement
Alan Crowther is head of EVERSANA’s global pricing platform Navlin.
Articles by Alan Crowther
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
2
The Battle to Own the GLP-1 Patient Journey
3
The Realistic Path to Making MFN Pricing Permanent
4
Roundup: Orbis Enters $1.4 Billion Partnership with Novo, Dualitas Therapeutics Enters Research collaboration with Roche, Aethlon Medical Merges with North Immunology
5